Silvio Danese

Dr. Silvio Danese

orcid

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 April 2020 in Nature Reviews Disease Primers
Verified
Journal Article
Closed access
PDF file
GRGiulia Roda
Giulia Roda
SNSiew Chien Ng
Siew Chien Ng
PKPaulo Gustavo Kotze
Paulo Gustavo Kotze
MAMarjorie Argollo
Marjorie Argollo
RPRemo Panaccione
Remo Panaccione
SDSilvio Danese
Silvio Danese

26 May 2022 in The Lancet
Verified
Journal Article
Closed access
SDSilvio Danese
Silvio Danese
SVSéverine Vermeire
Séverine Vermeire
WZWen Zhou
Wen Zhou
APAileen L Pangan
Aileen L Pangan
JSJesse Siffledeen
Jesse Siffledeen
RPRemo Panaccione
Remo Panaccione

1 June 2006 in Gastroenterology
Verified
Journal Article
Closed access
PDF file
SDSilvio Danese
Silvio Danese
MSMiquel Sans
Miquel Sans
CMCarol de la Motte
Carol de la Motte
CGCristina Graziani
Cristina Graziani
GWGail West
Gail West
CFClaudio Fiocchi
Claudio Fiocchi

1 February 2009 in Gastroenterology
Verified
Journal Article
Closed access
PDF file
FSFRANCO SCALDAFERRI
FRANCO SCALDAFERRI
SVStefania Vetrano
Stefania Vetrano
MSMiquel Sans
Miquel Sans
VAVincenzo Arena
Vincenzo Arena
GSGiuseppe Straface
Giuseppe Straface
SDSilvio Danese
Silvio Danese

23 November 2011 in Gut
Verified
Journal Article
Closed access
PDF file
SDSilvio Danese
Silvio Danese
The mechanisms underlying the chronic intestinal inflammation that is a hallmark of inflammatory bowel diseases (IBD) are complex. Components of the pathological response include the adaptive and innate immune systems, as well as the intestinal epithelium and endothelium. Advances in the understanding of the roles of each of these components have resulted in the development of multiple biological agents that all represent an alternative to the use of current therapies in patients with refractory Crohn's disease or ulcerative colitis. This study systematically reviews the mechanisms of action, efficacy and safety of new and emerging therapies that are currently in clinical trials and discusses future directions in the treatment of IBD.

7 December 2021 in Nature Reviews Gastroenterology & Hepatology
Verified
Journal Article
Closed access
PDF file
SDSilvia D’aLessio
Silvia D’aLessio
FUFederica Ungaro
Federica Ungaro
DNDaniele Noviello
Daniele Noviello
SLSara Lovisa
Sara Lovisa
Laurent Peyrin-birouletLaurent Peyrin-biroulet
Laurent Peyrin-biroulet
SDSilvio Danese
Silvio Danese